PubMed, July 23, 2020
Despite the success of several standards of care treatment options in metastatic castration-resistant prostate cancer (mCRPC), a significant number of patients attain therapeutic resistance and eventually develop disease progression. Moreover, managing these patients is currently challenging.
However, 225Ac-PSMA-617 targeted Alpha Therapy (TAT) in mCRPC showed promising disease control rate, even when all other therapeutic options were exhausted, with low treatment-related toxicities.